Highlights Altimmune, Inc.

Equities

ALT

US02155H2004

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 13:12:37 2025-12-05 EST			5-day change	1st Jan Change
5.275 ^USD	-0.66%		+0.10%	-26.98%

12-01	Altimmune, Inc. Announces CEO Changes	CI
12-01	Altimmune, Inc. Announces Executive Changes	CI

Highlights

Weight-loss drug developers line up to tap lucrative market as competition heats up	11-25	RE
Altimmune, Inc. Announces Publication of Impact Phase 2B Trial Data in the Lancet and Concurrent Late-Breaking Oral Presentation At Aasld the Liver Meeting®? 2025	11-11	CI
Weight-loss drug developers line up to tap lucrative market as competition heats up	11-10	RE
Altimmune, Inc. Presents Ai-Based Analysis of Liver Fibrosis Reduction from Impact Phase 2B Trial of Pemvidutide Inash in Late-Breaking Poster At Aasld the Liver Meeting®? 2025	11-07	CI
Altimmune Inc files for mixed shelf of up to $400 million - SEC filing	11-06	RE
Altimmune files for offering of common stock of up to $200 million - filing	11-06	RE
Altimmune, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	11-06	CI
Altimmune Q3 revenue beats expectations	11-06	RE
Altimmune, Inc. Announces Early Completion of Enrollment in RECLAIM Phase 2 Trial Evaluating Pemvidutide in Alcohol Use Disorder	11-03	CI
Metsera the US obesity biotech at centre of Novo, Pfizer bidding war	10-30	RE
Altimmune, Inc. Announces FDA Fast Track Designation for Pemvidutide in Alcohol Use Disorder	08-19	CI
Altimmune, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	08-12	CI
Altimmune, Inc. Announces Initiation of Restore Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol-Associated Liver Disease	07-09	CI
Altimmune shares slump as weight-loss drug's fatty liver trial data disappoints	06-26	RE
Altimmune to Announce Topline 24 Week Results from its IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH	06-25	CI
Altimmune, Inc. Announces Initiation of RECLAIM Phase 2 Trial Evaluating Efficacy and Safety of Pemvidutide in Alcohol Use Disorder	05-19	CI
Weight-loss drug developers line up to tap lucrative market as competition heats up	05-16	RE
Altimmune Q1 Net Income USD -19.575 Million	05-13	RE
Altimmune, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	05-13	CI
Pfizer ends development of weight-loss pill danuglipron	04-14	RE
Altimmune, Inc. Pursues Two Additional Indications for Its Lead Product Candidate, Pemvidutide	03-13	CI
Altimmune, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024	02-27	CI
Altimmune Reports 'Significant' Drop in Inflammatory Lipids With Pemvidutide in Liver Disease Treatment	11-15	MT
Altimmune, Inc. Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease at The Liver Meeting 2024	11-15	CI
Altimmune, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	11-12	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Altimmune, Inc.

Equities

ALT

US02155H2004

Biotechnology & Medical Research

Highlights

Filters